胆道癌的研究进展
Research Progress of Biliary Tract Cancers.
作者信息
Fonkoua Lionel Aurelien A Kankeu, Mahipal Amit
机构信息
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
出版信息
Cancers (Basel). 2021 Feb 22;13(4):919. doi: 10.3390/cancers13040919.
Abstract
This series of nine articles (three original articles, six reviews) is presented by international leaders in biliary tract cancers (BTC) [...].
摘要
这一系列九篇文章（三篇原创文章、六篇综述）由胆道癌（BTC）领域的国际领军人物撰写[……]
相似文献
1
Research Progress of Biliary Tract Cancers.胆道癌的研究进展
Cancers (Basel). 2021 Feb 22;13(4):919. doi: 10.3390/cancers13040919.
2
Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.胆道癌的家族风险：一项基于犹他州人群的研究。
Dig Dis Sci. 2016 Dec;61(12):3627-3632. doi: 10.1007/s10620-016-4310-3. Epub 2016 Sep 21.
3
[Advance in immunotherapy on biliary tract cancers].[胆道癌免疫治疗的进展]
Zhonghua Wai Ke Za Zhi. 2021 Feb 1;59(2):156-160. doi: 10.3760/cma.j.cn112139-20200515-00382.
4
Immunotherapy of biliary tract cancer.胆管癌的免疫治疗
Tumour Biol. 2016 Mar;37(3):2817-21. doi: 10.1007/s13277-015-4743-x. Epub 2016 Jan 4.
5
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations.胆道癌：流行病学、分子发病机制及遗传风险关联
Chin Clin Oncol. 2016 Oct;5(5):61. doi: 10.21037/cco.2016.10.09.
6
FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.法尼醇X受体激动剂通过小异二聚体蛋白依赖性抑制Bcl-xL表达增强胆管癌细胞对顺铂的敏感性。
Oncotarget. 2016 Jun 7;7(23):34617-29. doi: 10.18632/oncotarget.8964.
7
Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.紫藤凝集素唾液酸化粘蛋白核心多肽1是胆管癌和肝内胆管癌的敏感生物标志物：一项多中心研究。
J Gastroenterol. 2017 Feb;52(2):218-228. doi: 10.1007/s00535-016-1230-0. Epub 2016 Jun 29.
8
Clinical and Translational Research Challenges in Biliary Tract Cancers.胆道肿瘤临床与转化研究的挑战
Curr Med Chem. 2020;27(29):4756-4777. doi: 10.2174/0929867327666200123090153.
9
Surgical management of biliary tract cancers.胆道癌的外科治疗
Chin Clin Oncol. 2016 Oct;5(5):63. doi: 10.21037/cco.2016.10.03.
10
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).一项多机构试验（东京胆道癌研究组：TOSBIC01）中辅助替吉奥治疗可切除胆道癌一年的前瞻性可行性研究。
BMC Cancer. 2020 Jul 23;20(1):688. doi: 10.1186/s12885-020-07185-6.
本文引用的文献
1
Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation.部分无法切除的肝门部胆管癌（pCCA）患者可从肝移植中获得长期益处。
Cancers (Basel). 2020 Oct 27;12(11):3157. doi: 10.3390/cancers12113157.
2
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.CAP7.1作为晚期胆管癌二线治疗的疗效与安全性：一项随机II期研究的数据
Cancers (Basel). 2020 Oct 27;12(11):3149. doi: 10.3390/cancers12113149.
3
Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review.用于胆管癌诊疗的生物标志物翻译：一项系统综述
Cancers (Basel). 2020 Sep 30;12(10):2817. doi: 10.3390/cancers12102817.
4
Prevention and treatment of FGFR inhibitor-associated toxicities.成纤维细胞生长因子受体抑制剂相关毒性的预防和治疗。
Crit Rev Oncol Hematol. 2020 Nov;155:103091. doi: 10.1016/j.critrevonc.2020.103091. Epub 2020 Sep 1.
5
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.晚期/转移性胆管癌全身治疗的最新进展
Cancers (Basel). 2020 Sep 11;12(9):2599. doi: 10.3390/cancers12092599.
6
Role of Chemokines in the Biology of Cholangiocarcinoma.趋化因子在胆管癌生物学中的作用
Cancers (Basel). 2020 Aug 7;12(8):2215. doi: 10.3390/cancers12082215.
7
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.胆管癌的分子与免疫特征：向个性化医疗的范式转变
Cancers (Basel). 2020 Aug 6;12(8):2190. doi: 10.3390/cancers12082190.
8
Examination of Prognostic Factors Affecting Long-Term Survival of Patients with Stage 3/4 Gallbladder Cancer without Distant Metastasis.影响无远处转移的3/4期胆囊癌患者长期生存的预后因素分析
Cancers (Basel). 2020 Jul 27;12(8):2073. doi: 10.3390/cancers12082073.
9
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.晚期胆管癌的靶向治疗：一种不断发展的模式
Cancers (Basel). 2020 Jul 24;12(8):2039. doi: 10.3390/cancers12082039.
10
Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial.奥沙利铂、吉西他滨和卡培他滨或顺铂与吉西他滨治疗晚期胆管癌患者的随机II期试验
Cancers (Basel). 2020 Jul 20;12(7):1975. doi: 10.3390/cancers12071975.
Zotero 插件